VitaNova Life Sciences (VNOV) Gains from Investment Securities (2022 - 2026)

VitaNova Life Sciences has reported Gains from Investment Securities for 5 years, with the latest figure at -$77333.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 689.35% year-over-year to -$77333.0; the trailing twelve-month figure through Jan 2026 stood at $16698.0 (changed N/A YoY), and the FY2023 full-year result was $3880.0, changed N/A from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$77333.0, down from $94031.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $94031.0 in Q4 2025, with the low at -$77333.0 in Q1 2026.
• Historically, Gains from Investment Securities has averaged $2939.7 across 5 years, with a median of $3880.0 in 2022.
• Annual changes were most pronounced in 2025 — Gains from Investment Securities surged 859.79% — and 2026, when it plunged 689.35%.
• VitaNova Life Sciences' Gains from Investment Securities stood at -$3880.0 in 2022, then surged by 200.0% to $3880.0 in 2023, then soared by 152.5% to $9797.0 in 2024, then surged by 859.79% to $94031.0 in 2025, then sank by 182.24% to -$77333.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$77333.0 (Q1 2026), $94031.0 (Q4 2025), and -$9797.0 (Q1 2025), per Business Quant data.